A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant. The findings, reported on October 19, 2023 in the journal Biomedicine & Pharmacotherapy, were made in novel cellular models featuring TB-infected human cells that can help accelerate screening of potential TB drugs and therapies like this one. The open-access article is titled “Combination of MCL-1 and BCL-2 Inhibitors Is a Promising Approach for a Host-Directed Therapy for Tuberculosis.” The therapy evaluated in this study combines two molecules – one of which is already FDA-approved for use in cancer patients, and another that is being evaluated in Phase 1/2 clinical trials for cancer. The compounds help the body initiate its normal cell death processes in targeted areas, be it cancerous cells, or in this case, cells infected with Mycobacterium tuberculosis (M. tb), the bacterium that causes TB.
Login Or Register To Read Full Story